Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Inappropriate Use Of Homeostasis Model Assessment Cutoff Values For Diagnosing Insulin Resistance In Pediatric Studies, Carrie Fox Iii, Lourdes Bernardino, Jill Cochran, Mary Essig, Kristie Grove Bridges
Inappropriate Use Of Homeostasis Model Assessment Cutoff Values For Diagnosing Insulin Resistance In Pediatric Studies, Carrie Fox Iii, Lourdes Bernardino, Jill Cochran, Mary Essig, Kristie Grove Bridges
Clinical and Translational Science Institute
Background—Assessing pediatric patients for insulin resistance is one way to identify those who are at a high risk of developing type 2 diabetes mellitus. The homoeostasis model assessment (HOMA) is a measure of insulin resistance based on fasting blood glucose and insulin levels. Although this measure is widely used in research, cutoff values for pediatric populations have not been established. Objective—To assess the validity of HOMA cutoff values used in pediatric studies published in peer-reviewed journals. Methods—Studies published from January 2010 to December 2015 were identified through MEDLINE. Initial screening of abstracts was done to select studies that were conducted …
Structure-Activity And In Vivo Evaluation Of A Novel Lipoprotein Lipase (Lpl) Activator, Werner J. Geldenhuys, Joel Caporoso, Thomas C. Leeper, Yoon-Kwang Lee, Li Lin, Altaf S. Darvesh, Prabodh Sadana
Structure-Activity And In Vivo Evaluation Of A Novel Lipoprotein Lipase (Lpl) Activator, Werner J. Geldenhuys, Joel Caporoso, Thomas C. Leeper, Yoon-Kwang Lee, Li Lin, Altaf S. Darvesh, Prabodh Sadana
Clinical and Translational Science Institute
Elevated triglycerides (TG) contribute towards increased risk for cardiovascular disease. Lipoprotein lipase (LPL) is an enzyme that is responsible for the metabolism of core triglycerides of very-low density lipoproteins (VLDL) and chylomicrons in the vasculature. In this study, we explored the structure-activity relationships of our lead compound (C10d) that we have previously identified as an LPL agonist. We found that the cyclopropyl moiety of C10d is not absolutely necessary for LPL activity. Several substitutions were found to result in loss of LPL activity. The compound C10d was also tested in vivo for its lipid lowering activity. Mice were fed a …